Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Vered Caplan | F | 55 | 12 Jahre | |
| David Sidransky | M | 64 | 11 Jahre | |
| Mario Philips | M | 54 | 4 Jahre | |
| Yaron Adler | M | 54 | 12 Jahre | |
| Guy Yachin | M | 55 | 12 Jahre | |
| Sarah Ferber | M | 70 | 16 Jahre | |
| Ashish Nanda | M | 59 | 7 Jahre | |
| Victor Miller | M | 54 | - | |
| Gerhard Bauer | M | - | 1 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Neil Reithinger | M | 54 | 9 Jahre | |
| Elliot Maltz | M | 39 | - | |
| Manfred Rüdiger | M | 59 |
Cardion GmbH
 Cardion GmbH Medical SpecialtiesHealth Technology Cardion GmbH develops biopharmaceutical products. It integrates synergistic local gene delivery stem cell engineering and tolerance induction capabilities to build cardiovascular gene therapy products. The company is headquartered in Dusseldorf, Germany. | 5 Jahre |
| Claudia Zylberberg | M | - | - | |
| Osher Rheinisch | F | 52 | 1 Jahre | |
| Thomas Schulze | M | 61 |
Avontec GmbH
 Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | 7 Jahre |
| Thomas Mathers | M | 56 |
Cardion GmbH
Cardion GmbH Medical SpecialtiesHealth Technology Cardion GmbH develops biopharmaceutical products. It integrates synergistic local gene delivery stem cell engineering and tolerance induction capabilities to build cardiovascular gene therapy products. The company is headquartered in Dusseldorf, Germany. | 1 Jahre |
| Thomas H. Moll | M | 58 |
Cardion GmbH
Cardion GmbH Medical SpecialtiesHealth Technology Cardion GmbH develops biopharmaceutical products. It integrates synergistic local gene delivery stem cell engineering and tolerance induction capabilities to build cardiovascular gene therapy products. The company is headquartered in Dusseldorf, Germany. | 5 Jahre |
| Efrat Assa-Kunik | M | 49 | 2 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 14 | 77,78% |
| Deutschland | 4 | 22,22% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Heiko von der Leyen
- Persönliches Netzwerk
